Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Article Abstract:

The study shows that the sensitivity of the kidney cancer cells like the Von Hippel-Lindau tumor suppressor gene (VHL), to the kinase mammalian target of rapamycin (mTOR) is highly affected by the encoding hypoxia-inducible factor (HIF1A). The results show that the VHL-deficient tumors show increased uptake of the positron emission tomography (PET) tracer fluorodeoxyglucose (FDG) in an mTOR dependant manner and can be used as a pharmacodynamic marker in such settings.

California, Usage, Diagnosis, Cancer genetics, Rapamycin, PET imaging, Positron emission tomography, Von Hippel-Lindau disease

---

Molecular determinants of resistance to antiandrogen therapy

Article Abstract:

Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels, this androgen receptor conversion was connected with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. These discoveries provide insight toward the design of new antiandrogens.

Messenger RNA, Genetic research, Antiandrogens

---

Calculated resistance in cancer

Article Abstract:

The occurrence of resistance to molecularly targeted cancer therapy is discussed. The number of drug-resistant mutants can be dramatically restricted to a single point mutation in the gene encoding BCR-ABL by combining the drugs, imatinib and dastinib.

United States, Research and Development in the Physical, Engineering, and Life Sciences, Research and Testing Services, Cancer & Cell R&D, Cancer research, Drug resistance, Oncology, Experimental

Similar abstracts:

• Abstracts: Ergonomics debate evolves into an issue of mind over matter. Breaking down the budgets
• Abstracts: Manufacturer sends out alert over high start dose of statin. ANNOTATION: Supplement: The development of an accredited bowel-management course
• Abstracts: Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo
• Abstracts: Diabetes research investment in the European Union. After criticism, more modest cancer genome project takes shape

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.